Market Summary
USD57.77-0.52
Market Closed-0.89%
NVCR Stock Price
NVCR RSI Chart
NVCR Valuation
NVCR Price/Sales (Trailing)
NVCR Profitability
NVCR Fundamentals
NVCR Revenue
NVCR Earnings
Price Action
52 Week Range
56.06120.03
(Low)(High)
Last 7 days
-0.3%
Last 30 days
-24.3%
Last 90 days
-15.3%
Trailing 12 Months
-27.3%
NVCR Financial Health
NVCR Investor Care
Peers (Alternatives to Novocure)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 103.1B | 18.4B | 6.02% | 5.19% | 43.7 | 5.59 | 7.84% | 18.25% |
ISRG | 88.4B | 6.2B | 9.31% | -11.96% | 66.85 | 14.21 | 8.97% | -22.43% |
BSX | 69.2B | 12.7B | 2.81% | 11.10% | 99.12 | 5.46 | 6.68% | -32.95% |
BDX | 68.6B | 19.0B | 2.19% | -5.22% | 42.6 | 3.61 | -0.43% | -8.78% |
EW | 49.2B | 5.4B | 6.12% | -27.99% | 32.34 | 9.15 | 2.86% | 1.25% |
| MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 16.25% | 13.06% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.4B | 847.1M | 3.66% | 36.84% | -5.2K | 12.31 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -9.17% | -24.82% | 30.22 | 5.09 | 6.76% | 24.45% |
IRTC | 3.6B | 410.9M | 3.83% | -15.78% | -30.64 | 8.66 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 11.07% | -63.68% | -28.28 | 3.34 | 14.00% | -707.69% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 350.9M | 7.57% | 51.19% | -10.79 | 4.68 | 44.26% | -5.42% |
SILK | 1.6B | 138.6M | -27.43% | 0.81% | -28.66 | 11.37 | 36.62% | -10.44% |
AVNS | 1.3B | 820.0M | 0.91% | -12.65% | 26.12 | 1.61 | 10.13% | 701.59% |
CSII | 828.4M | 239.8M | 0.81% | -4.01% | -21.88 | 3.45 | -4.74% | -31.15% |
Financials for Novocure
| Income Statement (Last 12 Months) | (In Thousands) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -0.9% | 537,840 | 542,624 | 545,232 | 537,883 | 535,031 |
| Gross Profit | -0.9% | 422,973 | 426,958 | 429,109 | 421,664 | 420,154 |
| Operating Expenses | 3.1% | 512,496 | 496,901 | 482,993 | 466,715 | 464,487 |
| S&GA Expenses | 6.5% | 173,658 | 163,011 | 154,196 | 143,584 | 137,057 |
| R&D Expenses | -1.0% | 206,085 | 208,196 | 204,381 | 197,621 | 201,303 |
| EBITDA | -10.9% | -71,181 | -64,170 | -51,211 | -41,264 | - |
| EBITDA Margin | -11.9% | -0.13* | -0.12* | -0.09* | -0.08* | - |
| Earnings Before Taxes | -9.3% | -81,846 | -74,861 | -61,977 | -51,856 | -52,075 |
| EBT Margin | -10.3% | -0.15* | -0.14* | -0.11* | -0.10* | - |
| Interest Expenses | -59.4% | 41.00 | 101 | 101 | 101 | 101 |
| Net Income | -13.3% | -92,534 | -81,689 | -68,237 | -58,870 | -58,351 |
| Net Income Margin | -14.3% | -0.17* | -0.15* | -0.13* | -0.11* | - |
| Free Cahsflow | -52.1% | 9,430 | 19,698 | 24,084 | 36,007 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 1.5% | 1,192 | 1,174 | 1,163 | 1,150 | 1,139 |
| Current Assets | 0.8% | 1,112 | 1,102 | 1,095 | 1,081 | 1,074 |
| Cash Equivalents | -52.7% | 115 | 244 | 368 | 192 | 209 |
| Inventory | 9.6% | 29.00 | 27.00 | 30.00 | 29.00 | 24.00 |
| Net PPE | 9.9% | 33.00 | 30.00 | 27.00 | 25.00 | 23.00 |
| Liabilities | 3.0% | 750 | 729 | 721 | 714 | 729 |
| Current Liabilities | 12.5% | 159 | 141 | 135 | 128 | 143 |
| Long Term Debt | - | 562 | - | - | - | - |
| LT Debt, Non Current | 0.1% | 566 | 565 | 564 | 563 | 562 |
| Shareholder's Equity | -0.9% | 441 | 445 | 442 | 436 | 410 |
| Retained Earnings | -5.0% | -778 | -741 | -714 | -690 | -685 |
| Additional Paid-In Capital | 2.8% | 1,222 | 1,189 | 1,158 | 1,128 | 1,100 |
| Accumulated Depreciation | - | 22.00 | - | - | - | - |
| Shares Outstanding | 0.2% | 105 | 105 | 105 | 104 | 104 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -37.0% | 31.00 | 49.00 | 51.00 | 61.00 | 83.00 |
| Share Based Compensation | 7.4% | 107 | 100 | 99.00 | 101 | 95.00 |
| Cashflow From Investing | 72.6% | -139 | -510 | -58.04 | -216 | -144 |
| Cashflow From Financing | -1.5% | 15.00 | 16.00 | 15.00 | 21.00 | 26.00 |
Risks for NVCR
What is the probability of a big loss on NVCR?
99.6%
Probability that Novocure stock will be more than 20% underwater in next one year
80%
Probability that Novocure stock will be more than 30% underwater in next one year.
43.9%
Probability that Novocure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does NVCR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Novocure was unfortunately bought at previous high price.
Drawdowns
Returns for NVCR
Cumulative Returns on NVCR
24.1%
7-Year Cumulative Returns
22.3%
5-Year Cumulative Returns
-3.8%
3-Year Cumulative Returns
What are the long-term rolling returns for NVCR?
FIve years rolling returns for Novocure.
Annualized Returns
Which funds bought or sold NVCR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-23 | ETF MANAGERS GROUP, LLC | sold off | -100 | -3,751,000 | - | -% |
2023-03-17 | American Portfolios Advisors | reduced | -4.76 | 180 | 4,559 | -% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -0.56 | -27,137,200 | 650,163,000 | 0.68% |
2023-03-07 | Nordwand Advisors, LLC | new | - | 111,125,000 | 111,125,000 | 13.86% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -85.97 | -600,000 | 93,000 | -% |
2023-03-03 | TIAA, FSB | unchanged | - | -7,718 | 215,282 | -% |
2023-02-28 | Voya Investment Management LLC | added | 8.68 | 1,100,570 | 23,496,600 | 0.03% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | -241,000 | 6,733,000 | 0.07% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -330 | 14,670 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 13.25 | 502,148 | 5,886,150 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Novocure News
Schedule 13G FIlings of Novocure
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital international investors | 7.8% | 8,155,909 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 12.3% | 12,899,395 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.10% | 9,547,336 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.2% | 7,605,425 | SC 13G/A | |
| Jan 23, 2023 | baillie gifford & co | 8.45% | 8,863,842 | SC 13G/A | |
| Apr 11, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 11, 2022 | capital world investors | 12.3% | 12,723,214 | SC 13G/A | |
| Feb 11, 2022 | capital international investors | 11.1% | 11,531,075 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
NVCR Fair Value
Novocure fair value in different scenarios
The table shows the Fair Value estimates for Novocure for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 1.42 -97.54% | 2.29 -96.04% | 4.40 -92.38% | 8.72 -84.91% | 17.51 -69.69% |
| Current Inflation | 1.37 -97.63% | 2.14 -96.30% | 3.97 -93.13% | 7.67 -86.72% | 15.15 -73.78% |
| Very High Inflation | 1.31 -97.73% | 1.96 -96.61% | 3.46 -94.01% | 6.44 -88.85% | 12.43 -78.48% |
Historical Novocure Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Novocure
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for NVCR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-07 | Leonard Frank X | sold | -625,205 | 75.1629 | -8,318 | president, cns cancers us |
2023-03-03 | GROENHUYSEN WILHELMUS CM | acquired | - | - | 51,986 | chief operating officer |
2023-03-03 | Weinberg Uri | acquired | - | - | 32,766 | chief innovation officer |
2023-03-03 | Shah Pritesh | sold | -1,631,410 | 76.1594 | -21,421 | chief growth officer |
2023-03-03 | Cordova Ashley | acquired | - | - | 11,808 | chief financial officer |
2023-03-03 | Burke William Patrick | sold | -45,162 | 76.1594 | -593 | chief human resources officer |
2023-03-03 | Leonard Frank X | acquired | - | - | 11,808 | president, cns cancers us |
2023-03-03 | Leonard Frank X | sold | -159,859 | 77.6391 | -2,059 | president, cns cancers us |
2023-03-03 | GROENHUYSEN WILHELMUS CM | sold | -1,952,350 | 76.1594 | -25,635 | chief operating officer |
2023-03-03 | Shah Pritesh | acquired | - | - | 47,182 | chief growth officer |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
NVCR Income Statement
2022-12-31Consolidated statements of operations - USD ($) $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Income Statement [Abstract] | |||
| Net revenues | $ 537,840 | $ 535,031 | $ 494,366 |
| Cost of revenues | 114,867 | 114,877 | 106,501 |
| Gross profit | 422,973 | 420,154 | 387,865 |
| Operating costs and expenses: | |||
| Research, development and clinical studies | 206,085 | 201,303 | 132,010 |
| Sales and marketing | 173,658 | 137,057 | 118,017 |
| General and administrative | 132,753 | 126,127 | 107,437 |
| Total operating costs and expenses | 512,496 | 464,487 | 357,464 |
| Operating income (loss) | (89,523) | (44,333) | 30,401 |
| Financial (expenses) income, net | 7,677 | (7,742) | (12,299) |
| Income (loss) before income taxes | (81,846) | (52,075) | 18,102 |
| Income tax | 10,688 | 6,276 | (1,706) |
| Net income (loss) | $ (92,534) | $ (58,351) | $ 19,808 |
| Basic net income (loss) per ordinary share (in usd per share) | $ (0.88) | $ (0.56) | $ 0.20 |
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 104,660,476 | 103,433,274 | 100,930,866 |
| Diluted net income (loss) per ordinary share (in usd per share) | $ (0.88) | $ (0.56) | $ 0.18 |
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 104,660,476 | 103,433,274 | 108,877,648 |
NVCR Balance Sheet
2022-12-31Consolidated balance sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 115,326 | $ 208,802 |
| Short-term investments | 854,099 | 728,898 |
| Restricted cash | 508 | 807 |
| Trade receivables, net | 86,261 | 93,567 |
| Receivables and prepaid expenses | 25,959 | 17,025 |
| Inventories | 29,376 | 24,427 |
| Total current assets | 1,111,529 | 1,073,526 |
| Long-term assets: | ||
| Property and equipment, net | 32,678 | 22,693 |
| Field equipment, net | 12,684 | 12,923 |
| Right-of-use assets | 23,596 | 18,267 |
| Other long-term assets | 11,161 | 12,086 |
| Total long-term assets | 80,119 | 65,969 |
| Total assets | 1,191,648 | 1,139,495 |
| Current liabilities: | ||
| Trade payables | 85,197 | 72,600 |
| Other payables, lease liabilities and accrued expenses | 73,580 | 70,002 |
| Total current liabilities | 158,777 | 142,602 |
| Long-term liabilities: | ||
| Long-term debt, net | 565,509 | 562,216 |
| Deferred revenues | 2,878 | 6,477 |
| Long term leases | 18,762 | 12,997 |
| Employee benefit liabilities | 4,404 | 4,543 |
| Other long-term liabilities | 148 | 166 |
| Total long-term liabilities | 591,701 | 586,399 |
| Total liabilities | 750,478 | 729,001 |
| Commitments and contingencies | ||
| Shareholders’ equity: | ||
| Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 105,049,411 shares and 103,971,263 shares at December 31, 2022 and December 31, 2021 respectively; | 0 | 0 |
| Additional paid-in capital | 1,222,063 | 1,099,589 |
| Accumulated other comprehensive income (loss) | (2,433) | (3,169) |
| Retained earnings (accumulated deficit) | (778,460) | (685,926) |
| Total shareholders’ equity | 441,170 | 410,494 |
| Total liabilities and shareholders’ equity | $ 1,191,648 | $ 1,139,495 |